

Dear Colleague:

We are pleased to inform you that we are participating in a phase III clinical research trial of a new investigational compound (RTH258 solution for intravitreal administration) for the treatment of Neovascular Age-Related Macular Degeneration.

The study compares RTH258 to aflibercept. Eligible patients will be 50 years of age or older with the following main inclusion and exclusion criteria:

Main Inclusion Criteria:

- Active choroidal neovascularization (CNV) lesions due to AMD that affect the central subfield
- Total area of CNV (including both classic and occult components) must comprise > 50% of the total lesion area

Main Exclusion Criteria:

- Study eye must not have been treated for neovascular AMD previously
- Study eye must not have any current or history of concurrent intraocular condition other than neovascular AMD
- Study eye must not have uncontrolled glaucoma and/or must not be missing a lens

We would appreciate your referral of any patient who may be interested and eligible to participate and potentially benefit from this investigational treatment.

Thank you in advance for your support and we look forward to hearing from you.

With best regards,

James Earl, MD, PhD  
Denton Roberts, MD